Knight Therapeutics Inc. (KHTRF)

OTCMKTS · Delayed Price · Currency is USD
4.040
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT
23.17%
Market Cap 406.28M
Revenue (ttm) 246.87M
Net Income (ttm) -15.51M
Shares Out n/a
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100
Open 4.540
Previous Close 4.540
Day's Range 4.040 - 4.540
52-Week Range 3.260 - 4.550
Beta 0.50
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About Knight Therapeutics

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Ne... [Read more]

Sector Healthcare
Founded 2013
Employees 725
Stock Exchange OTCMKTS
Ticker Symbol KHTRF
Full Company Profile

Financial Performance

In 2023, Knight Therapeutics's revenue was 328.20 million, an increase of 11.80% compared to the previous year's 293.56 million. Losses were -16.84 million, -43.68% less than in 2022.

Financial numbers in CAD Financial Statements

News

Knight Therapeutics Inc. places No. 397 on The Globe and Mail’s sixth annual ranking of Canada’s Top Growing Companies

MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s rankin...

4 weeks ago - Financial Post

Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine's ranki...

4 weeks ago - GlobeNewsWire

Andrey Omelchak's Top Picks:Lumine, Trisura Group, and Knight Therapeutics

Andrey Omelchak, president and CIO at LionGuard Capital Management, discusses his top picks: Lumine, Trisura Group, and Knight Therapeutics.

7 weeks ago - BNN Bloomberg

Knight Therapeutics Reports Second Quarter 2024

MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported financial ...

2 months ago - GlobeNewsWire

Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call

MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024 finan...

3 months ago - GlobeNewsWire

Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript

Knight Therapeutics, Inc. (OTCPK:KHTRF) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind Utchanah - CFO Conference ...

6 months ago - Seeking Alpha

Knight Therapeutics Reports First Quarter 2024 Results

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial re...

6 months ago - GlobeNewsWire

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusi...

6 months ago - GlobeNewsWire

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin...

6 months ago - GlobeNewsWire

Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financi...

6 months ago - GlobeNewsWire

Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript

Knight Therapeutics Inc. (KHTRF) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...

7 months ago - GlobeNewsWire

Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year ...

8 months ago - GlobeNewsWire

Knight Therapeutics Inc. Celebrates its First Decade of Success

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year ann...

8 months ago - GlobeNewsWire

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, Unit...

9 months ago - GlobeNewsWire

Knight Therapeutics Announces Launch of Bijuva® in Canada

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol ...

9 months ago - GlobeNewsWire

Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY® in Canada....

10 months ago - GlobeNewsWire

Knight Therapeutics Inc. (KHTRF) Q3 2023 Earnings Call Transcript

Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Samira Sakhia - President and Chief Executive Officer Arvind Utchanah - Chief F...

1 year ago - Seeking Alpha

Knight Therapeutics Reports Third Quarter 2023 Results

MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...

1 year ago - GlobeNewsWire

Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call

MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financ...

1 year ago - GlobeNewsWire

Knight Therapeutics Inc. places No. 90 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies

MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada's To...

1 year ago - GlobeNewsWire

Knight Therapeutics, Inc. (KHTRF) Q2 2023 Earnings Call Transcript

Knight Therapeutics, Inc. (OTCPK:KHTRF) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Samira Sakhia - President, CEO & Director Arvind Utchanah - CFO Amal Khouri - C...

1 year ago - Seeking Alpha

Knight Therapeutics Reports Second Quarter 2023 Results

MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial r...

1 year ago - GlobeNewsWire

Notice of Knight Therapeutics' Second Quarter 2023 Results Conference Call

MONTREAL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2023 finan...

1 year ago - GlobeNewsWire

Knight Therapeutics Inc. (KHTRF) Q1 2023 Earnings Call Transcript

Knight Therapeutics Inc. (OTCPK:KHTRF) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Samira Sakhia – President and Chief Executive Officer Arvind Utchanah – Chief Finan...

1 year ago - Seeking Alpha